LivaNova PLC, a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment company dedicated to investments in the healthcare and sustainability sector, announced that they are entering a agreement whereby entities funded and controlled by Gyrus will acquire LivaNova's heart valve (HV) business. LivaNova's Board of Directors has unanimously approved the divestment, which will allow the Company to sharpen its focus within its primary platforms, neuromodulation and cardiovascular, and devote more resources to executing its promising pipeline opportunities. Once the transaction is completed,

This announcement is officially valid in the original source language. Translations are only intended as a reading aid and should be compared with the text in the source language, which is the only one legally valid.

Contacts
LivaNova PLC Investor Relations and Media Contacts
 
Melissa Farina, +1 (281) 228-7262
VP, Investor Relations
InvestorRelations@livanova.com
 
Deanna Wilke, +1 (281) 727-2764
VP, Corporate Communications
Corporate.Communications@livanova.com

Source: businesswire.com